[D-Arg25]-Neuropeptide Y (human)

[D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY), a Y1 receptor selective agonist, plays a role in Alzheimer's disease (AD) and safeguards rat cortical neurons from β-Amyloid toxicity [1].

[D-Trp34]-Neuropeptide Y Acetate is a potent and selective agonist of neuropeptide Y (NPY) Y5 receptor. [D-Trp34]-Neuropeptide acetate Y is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y Acetate markedly increases food intake in rats.

Neuropeptide Y (scrambled) Acetate (Pro-Neuropeptide Y (scrambled) Acetate) is a scrambled peptide of Neuropeptide Y that has been implicated in Alzheimer's disease (AD) and may have neuroprotective effects.

H-D-Phe-Pip-Arg-pNA dihydrochloride (S-2238 dihydrochloride), a chromogenic substrate, mimics the N-terminal fragment of the A alpha chain of fibrinogen, the native substrate of thrombin. Specifically designed for thrombin detection, H-D-Phe-Pip-Arg-pNA dihydrochloride is employed for the quantification of antithrombin-heparin cofactor (AT-III). The AT-III assay utilizing this substrate is characterized by its sensitivity, accuracy, and ease of implementation.

Neuropeptide SF (human) aceate is a neuropeptide that augmented paraventricular CRH release and increased ACTH and corticosterone levels in the plasma.

RFRP-1 (human) acetate is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, eject

Neuropeptide AF (human) acetate (Neuropeptide AF (human) acetate (192387-38-5 Free base)) is an anti-opioid neuropeptide, a Neuropeptide AF (human) derivative, which regulates adipocyte metabolism.

Neuropeptide Y (29-64), amide, human acetate is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

High affinity neuropeptide Y Y1 receptor agonist

D-Lys(Z)-Pro-Arg-pNA (diacetate) diacetate is a chromogenic substrate.

'(Des-Bromo)-Neuropeptide B (1-23) (human)' is an agonist for orphan G-protein-coupled receptors, exhibiting a K i of 1.2 nM for GPR7 (NPBW1) and 341 nM for GPR8 (NPBW2) respectively [1].

Cyclo(Arg-Gly-Asp-D-Phe-Val) is an integrin αvβ3 inhibitor with antitumor properties, utilized in the research of acute myeloid leukemia [1].

(Asn10,Leu11,D-Trp12)-pTH-Related Protein (7-34) amide (human, mouse, rat) is a potent antagonist of the PTH-1R [1] [2].

Neuropeptide Y (NPY) is a 36-amino acid neuropeptide that exerts its activity via G-protein-coupled receptors. NPY is widely distributed in the peripheral and central nervous systems. It modulates a variety of physiological processes, e.g. the central reg

Neuropeptide W-23(human) (NPW-23) is an endogenous ligand for NPBW1 and NPBW2.

G-{d-Arg}-GDSPASSK is a polypeptide that inhibits cell adhesion, facilitates wound healing, and promotes tissue repair [1].

Neuropeptide W-23 (human) (NPW-23) TFA, representing the active form of Neuropeptide W, functions as an endogenous agonist for both NPBW1 (GPR7) and NPBW2 (GPR8) receptors [1].

Neuropeptide AF (93-110), Human is an endogenous antiopioid peptide.

Potent neuropeptide Y (NPY) Y5 receptor agonist (pEC50 values are 7.82, 6.28, 6.44 and > 6 at rat Y5, Y4, Y1 and Y2 receptors respectively) that displays > 26-fold, > 1000-fold and > 1000-fold selectivity over Y1, Y2 and Y4 receptors respectively. Induces

G-{d-Arg}-GDSP, an RGD peptide analogue, binds to the adhesion receptor of integrins, inhibiting cellular attachment to fibronectin and osteoclast resorption [1].

Neuropeptide Y (29-64), amide, human is a biologically active 36-amino acid peptide.

Highly potent GIP receptor agonist (EC50 = 630 ± 119 pM). Displays equivalent cAMP stimulating properties and improved resistance to enzymatic degradation compared to native GIP in cells expressing wild type GIP receptor. Improves glucose tolerance, insul

Biotinyl-neuropeptide W-23 (human) is a biotinylated form of neuropeptide W-23 (human), which functions as an agonist for the NPBW1 (GPR7) and NPBW2 (GPR8) receptors [1] [2].

(D-Ala2)-GRF (1-29) amide (human) is a potent superagonist of Growth Hormone-Releasing Factor (GRF), demonstrating an exceptionally high Growth Hormone (GH)-releasing activity, approximately 50-fold greater than that of GRF (1-29) in both pigs and rats [1].

Neuropeptide Y (3-36) (human, rat) is a metabolite of neuropeptide Y (NPY) generated by dipeptidyl peptidase-4 (DPP4). Known as a selective Y2 receptor agonist, Neuropeptide Y (3-36) (human, rat) effectively reduces the release of norepinephrine via the Y2 receptor[1][2].

S 2238 is a chromogenic substrate for thrombin that is used in amidolytic assay.

High affinity neuropeptide Y Y1 receptor agonist (Ki = 0.39 nM). Also shows affinity for Y4 and Y5 receptors.

Neuropeptide SF (human) considerably increases the amplitude of the sustained current of heterologously expressed ASIC3 (12-fold vs. 19- and nine-fold for FMRFamide and NPFF, respectively) with an EC50 of ~50 μM.

Gp100 (25-33), human is the amino acids 25-33 fragment of the human melanoma antigen. It is a 9-amino acid (AA) epitope restricted by H-2Db and recognized by the T cells.This is amino acids 25 to 33 fragment of human melanoma antigen gp100. This H-2Db res

Neuropeptide Y (1-24) (human) is a neuropeptide that inhibits the electrically stimulated twitch response in rat vas deferens and activates neurons in the rat CA3 region of the dorsal hippocampus in vivo following N-methyl-D-aspartate (NMDA) induction [1] [2].

[Ala11,D-Leu15]-Orexin B(human) TFA is a potent, selective agonist for the orexin-2 receptor (OX2), demonstrating 400-fold higher selectivity for OX2 (EC 50 =0.13 nM) compared to the orexin-1 receptor (OX1) with an EC 50 of 52 nM.

Neuropeptide Y (13-36), amide, human is a neuropeptide Y receptor agonist.

Neuropeptide Y(29-64) is a 36 amino acid peptide, a fragment of Neuropeptide Y.

Neuropeptide Y (NPY) (3-36) is a C-terminal fragment of NPY, a neuropeptide involved in controlling appetite, blood pressure, cardiac contractility, and intestinal secretion. NPY (3-36) is an endogenous peptide produced by cleavage of NPY by dipeptidyl peptidase 4 (DPP-4). It binds selectively to the NPY receptor Y2 (Ki = 0.41 nM in CHP 234 cells) over the Y1 receptor, where it does not bind at concentrations up to 1 μM. NPY (3-36) (0.1 nM) increases migration of human umbilical vein endothelial cells (HUVECs) by 80% after 12 hours in an in vitro wound closure assay. NPY (3-36) corresponds to residues 3-36 of the human and rat protein sequence.

H-D-Phe-Pip-Arg-pNA hydrochloride, a chromogenic substrate, mimics the N-terminal segment of the A alpha chain of fibrinogen, the native substrate of thrombin. It displays specificity towards thrombin and is employed for quantifying antithrombin-heparin cofactor (AT-III). The utilization of H-D-Phe-Pip-Arg-pNA hydrochloride in the AT-III assay enables a sensitive, accurate, and straightforward measurement process.

Amyloid-β (25-35) (Aβ (25-35)) is an 11-residue fragment of the Aβ protein that retains the physical and biological characteristics of the full length peptide. It forms fibrils that react to thioflavin T and Congo red and are organized in a cross-β arrangement of β-strands similar to Aβ (1-40) and Aβ (1-42) fibrils. Aggregated Aβ (25-35) decreases the viability of rat adrenal PC12 cells. It also decreases the viability of primary rat cortical neurons at concentrations ranging from 1 nM to 30 μM. In vivo, intracerebral injection of Aβ (25-35) (20 nmol) in rats induces lesions of neuronal and tissue loss. Aggregated Aβ (25-35) administered intracerebroventricularly to rats induces learning and memory impairments in the Y-maze, novel object recognition, and contextual fear conditioning tests.

Hepcidin-25 (human) acetate is a modulator of iron metabolism that demonstrates anti-inflammatory and antibacterial effects through the modulation of iron-mediated oxidant injury [1].

Z-D-Arg-OH is an amino acid derivative and has a wide range of applications in life science related research.

Neuropeptide Y (porcine), a peptide found in the porcine brain, effectively inhibits secretin-stimulated pancreatic secretion [1].

[Leu31,Pro34]-Neuropeptide Y(human,rat) TFA acts as a specific agonist for the neuropeptide Y Y1 receptor, while also activating receptors Y4 and Y5. This compound is known to elevate blood pressure in anesthetized rats and enhance food intake [1] [2].

[D-Trp34]-Neuropeptide Y TFA acts as a potent and selective agonist for the neuropeptide Y (NPY) Y5 receptor, demonstrating significantly lower potency at the NPY Y1, Y2, Y4, and Y6 receptors. It has been observed to significantly increase food intake in rats [1] [2].

Hepcidin-25 (human), an iron metabolism modulator, exhibits both anti-inflammatory and antibacterial activity through the modulation of iron-mediated oxidant injury [1].

H-D-Phe-Pip-Arg-pNA (S-2238) acetate is a chromogenic substrate designed based on the N-terminal fragment of the A alpha chain of fibrinogen, which is the physiological target of thrombin. As a specific indicator of thrombin activity, H-D-Phe-Pip-Arg-pNA acetate is utilized to quantify. This assay, utilizing H-D-Phe-Pip-Arg-pNA acetate, ensures high sensitivity, accuracy, and ease of execution.

[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) is an analog of GRF and a vasoactive intestinal peptide (VIP) antagonist.

Boc-D-Arg(Pbf)-OH is an amino acid derivative and has a wide range of applications in life science related research.

Neuromedin U (NMU) is a neuropeptide first demonstrated to drive smooth muscle contraction.1Translated as a 174 amino acid propeptide, NMU is cleaved to different lengths in different animals. It has diverse receptor-mediated rolesin vivo, as it regulates feeding, vasoconstriction, nociception, and bone remodeling and contributes to obesity, cancer and septic shock.2,2NMU-25 is the active form of NMU in humans. It binds with high affinity to receptors on human left ventricle and coronary artery (KDs = 0.26 and 0.11 nM, respectively), eliciting endothelium-independent vasoconstriction.3NMU-25 also suppresses glucose-stimulated insulin secretion in human islets, and this effect is lost in NMU R165W mutants, resulting in early-onset obesity.4 1.Mitchell, J.D., Maguire, J.J., and Davenport, A.P.Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SBritish Journal of Pharmacology15887-103(2009) 2.Greenwood, H.C., Bloom, S.R., and Murphy, K.G.Peptides and their potential role in the treatment of diabetes and obesityRev.Diabet.Stud.8(3)355-368(2011) 3.Mitchell, J.D., Maguire, J.J., Kuc, R.E., et al.Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular systemCardiovascular Research81353-361(2009) 4.Alfa, R.W., Park, S., Skelly, K.R., et al.Suppression of insulin production and secretion by a decretin hormoneCell Metabolism21(2)323-333(2015)

Galanin (1-13)-Neuropeptide Y (25-36) amide exhibits high-affinity binding to galanin receptors, similar to that of galanin itself [1].

D-Pro-Phe-Arg-Chloromethylketone, an inhibitor of coagulation factor XII and plasma kallikrein, is significant in the regulation of thrombosis and inflammation [1].

Ac-DArg-c[Cys-Glu-His-DPhe-Arg-Trp-Cys]-NH2 is a synthetic cyclic octapeptide that exhibits melanocortin-4 receptor (MC4R) agonism and has been shown to significantly elevate heart rate and blood pressure [1].

Acetyl-(D-Arg2)-GRF (1-29) amide (human) serves as an antagonist to growth hormone-releasing factor (GRF) and inhibits growth hormone (GH) secretion, with applications in endocrine research [1].